Anna Sofie Kappel Buhl

Anna Sofie Kappel Buhl

Auto-generated profile, based on publicly available information

Anna Sofie Kappel Buhl

Department of Pediatrics and Adolescent Medicine Copenhagen University Hospital, Rigshospitalet Copenhagen Denmark

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2020 in Applied Immunohistochemistry & Molecular Morphology
Verified
Journal Article
Closed access
SJSofie S. Mb Jespersen
Sofie S. Mb Jespersen
ESElisabeth S. Stovgaard
Elisabeth S. Stovgaard
DNDorte Dmsc Nielsen
Dorte Dmsc Nielsen
TCTroels D. Christensen
Troels D. Christensen
ABAnna S.K. Buhl
Anna S.K. Buhl
EBEva Balslev
Eva Balslev
Secreted phospholipase A2 group IIa (sPLA2-IIa) has been shown to promote tumor genesis and cell proliferation. The properties of this group of enzymes are utilized in liposomal drug delivery of chemotherapy. sPLA2-IIa is also under investigation as a possible treatment target in itself, and as a prognostic marker. The expression of sPLA2-IIa in breast cancer has not been examined extensively, and never using immunohistochemistry. We sought to investigate the expression of sPLA2-IIa in a cohort of advanced breast cancer patients with correlation to known clinicopathologic risk factors and survival. Material from 525 breast cancer patients (426 primary tumors and 99 metastases or local recurrences) was examined for sPLA2-IIa expression using immunohistochemistry. Out of these, 262 showed expression of sPLA2-IIa. We found that there was no correlation to clinicopathologic characteristics, and no impact of sPLA2-IIa expression on prognosis. However, we found that a large proportion of patients in our study had high levels of sPLA2-IIa expression, and that sPLA2-IIa was equally expressed in primary tumors and metastases. These findings may be significant in the future development of liposomal drug delivery or targeted sPLA2-IIa treatment.

11 August 2018 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
ABAnna Sofie Kappel Buhl
Anna Sofie Kappel Buhl
TCTroels Dreier Christensen
Troels Dreier Christensen
ICIb Jarle Christensen
Ib Jarle Christensen
KNKnud Mejer Nelausen
Knud Mejer Nelausen
EBEva Balslev
Eva Balslev
PJPeter Buhl Jensen
Peter Buhl Jensen
Anthracyclines remain a cornerstone in the treatment of primary and advanced breast cancer (BC). This study has evaluated the predictive value of a multigene mRNA-based drug response predictor (DRP) in the treatment of advanced BC with epirubicin. The DRP is a mathematical method combining in vitro sensitivity and gene expression with clinical genetic information from > 3000 clinical tumor samples.


8 September 2025 in Targeted Oncology
Verified
Journal Article
Open access
PDF file
TYTianwu Yang
Tianwu Yang
ARAnna Sofie Buhl Rasmussen
Anna Sofie Buhl Rasmussen
AWAllan Weimann
Allan Weimann
MTMaria Thastrup
Maria Thastrup
CRCecilie Utke Rank
Cecilie Utke Rank
TLTrine Meldgaard Lund
Trine Meldgaard Lund
Background Population pharmacokinetic models can potentially provide suggestions for an initial dose and the magnitude of dose adjustment during therapeutic drug monitoring procedures of imatinib. Several population pharmacokinetic models for imatinib have been developed over the last two decades. However, their predictive performance is still unknown when extrapolated to different populations, especially children. Objective This study aimed to evaluate the predictive performance of these published models on an external real-world dataset containing data from both adults and children. Methods A real-world dataset was collected, containing observations from adult and pediatric patients with Philadelphia chromosome-positive/Philadelphia chromosome-like acute lymphoblastic leukemia and chronic myeloid leukemia (N = 39) treated with imatinib. A systematic review through PubMed was conducted to identify qualified population-pharmacokinetic models for external evaluation (i.e., prediction-based, simulation-based, and Bayesian forecasting diagnostics). Standard allometric scaling was used for models that were developed based on data from adults only. Results Fifteen published models were found for evaluation, of which only two were based on data from both children and adults. Prediction-based diagnostics showed that some models had an acceptable level of bias. The model by Shriyan et al. (with allometric scaling) performed best with a median prediction error of 1.24%. However, no models performed well on precision even when allometric scaling was used, where the lowest median absolute prediction error was 37.66% using the model by Schmidli et al. The models by Golabchifar et al. and Schmidli et al. (both with allometric scaling) performed the best of all tested models, with a median prediction error ≤ 15%, median absolute prediction error ≤ 40%, fraction of prediction error within ± 20% (F20) ≥ 0.3, and within ± 30% (F30) nearly 0.4. Simulation-based diagnostics showed that most of the observations outside the 90% prediction interval were from children. Bayesian forecasting showed that the model prediction could be improved using one prior sample, particularly in adults. Conclusions Current models fail to accurately predict imatinib plasma concentrations in our real-world dataset, especially for children. Future pharmacokinetic studies should focus on developing better models for pediatric populations.

16 July 2025 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Open access
PDF file
MKMathilde Rønne Koch
Mathilde Rønne Koch
ARAnna Sofie Buhl Rasmussen
Anna Sofie Buhl Rasmussen
BABodil Als-Nielsen
Bodil Als-Nielsen
XDXimo Duarte
Ximo Duarte
GEGabriele Escherich
Gabriele Escherich
LTLinea Natalie Toksvang
Linea Natalie Toksvang
Purpose: Adherence to 6-mercaptopurine (6-MP)/methotrexate maintenance treatment for acute lymphoblastic leukemia (ALL) is pivotal to preventing relapse, and the 6-MP metabolite DNA-incorporated thioguanine (DNA-TG) is associated with relapse risk. In the ALLTogether-1 (A2G1) Maintenance sub-study (EU CT nr 2022-501050-11-01), DNA-TG, thioguanine nucleotides (TGN), and methylated mercaptopurine metabolites (MeMP) are analyzed regularly. Upon levels below preset limits (TGN < 50, or MeMP < 200 or < 100 nmol/mmol hemoglobin for thiopurine S-methyltransferase (TPMT) wild type and heterozygous patients, respectively), the treating physician is informed of potential non-adherence. We investigated the feasibility of using DNA-TG as the primary flagging of potential non-adherence. Methods: We analyzed 6-MP metabolites in 3,074 blood samples from 368 children enrolled in the A2G1 Maintenance sub-study. Results: In 6% of samples, TGN (median 212, 95% range 40–642), MeMP (median 4,959, 95% range 135–23,880) or both were below the flagging potential non-adherence limits. DNA-TG was associated with TGN (estimate = 1.72, p < 0.0001), MeMP (estimate = 1.10, p < 0.0001), and prescribed 6-MP dose (estimate = 1.083 and 1.132, p < 0.0001, for TPMT wild type and heterozygous patients) in linear effects models, and the predicted probability of treatment interruption in logistic regression models. DNA-TG was below 200 fmol TG/µg DNA (13th percentile of all measurements, median 569, 95% range 73–1,823) in all samples with both TGN and MeMP below the flagging potential non-adherence limits. Conclusion: DNA-TG can provide a cost-effective guidance on when to measure TGN and MeMP to determine whether non-adherence should be suspected, which is an additional benefit to monitoring DNA-TG during maintenance therapy.

22 September 2026 in Clinical Pharmacokinetics
Verified
Journal Article
Open access
PDF file
TYTianwu Yang
Tianwu Yang
MTMaria Thastrup
Maria Thastrup
TMTania Nicole Masmas
Tania Nicole Masmas
HUHilde Hylland Uhlving
Hilde Hylland Uhlving
JNJacob Nersting
Jacob Nersting
TLTrine Meldgaard Lund
Trine Meldgaard Lund
Background and Objectives Busulfan, used in conditioning regimens prior to haematopoietic stem cell transplantation, has a narrow therapeutic index; therefore, due to pharmacokinetic variability, therapeutic drug monitoring (TDM) is employed to ensure drug exposure levels associated with optimal clinical outcomes. This study aimed to facilitate dose adjustment and potentially reduce the number of samples required for TDM in clinical practice. Methods Population pharmacokinetic (popPK) and machine learning (ML) models (Random Forest and XGBoost) were developed using a local, retrospective, extensive-sampling dataset of 67 children (637 observations, Denmark) and externally evaluated using prediction error (PE) on a TDM dataset from another centre with 171 children (1871 observations, Netherlands). Limited sampling schedules were evaluated for both methods. Results A one-compartment model was the best data fit, showing time-varying clearance decreases of 10.4% and 13% on Days 2 and 3, respectively, compared to Day 1. The popPK, Random Forest, and XGBoost models performed well on the external dataset for concentration prediction, with median PE ranging from −4.82 to −7.44%, median absolute PE of approximately 15%, and approximately 80% of data predicted within ±30% of the PE. Sampling strategies at 0, 0.5, 1, 4 h or 0, 1, 2, 4 h post-infusion adequately predicted busulfan plasma concentration and exposure using the popPK model. Conclusions A new popPK model was developed to support individualised dose adjustments in children using fewer blood samples. Both Random Forest and XGBoost could predict busulfan's plasma concentration with performance like that of the popPK model (population prediction). However, a larger dataset is needed for ML methods to describe a complete pharmacokinetic profile.